We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Assay Targets Antibiotic Resistance with Pathogen Identification

By LabMedica International staff writers
Posted on 18 Feb 2019
A rapid diagnostic device has been developed to detect and identify the source of an infection in less than one hour. More...
The proprietary DNA-based technology has the potential to revolutionize infection control by providing a POC, inexpensive, rapid diagnosis of pathogens in humans, animals and agriculture.

The C-AST assay is being developed in tandem with the CAPTURE pathogen identification assay, which stands for confirm active pathogens through an amplified RNA expression platform. The CAPTURE assay identifies bacterial or fungal pathogens' RNA in liquid samples, including blood, urine, saliva, and other types, with a "universal fluorescent marker," applying the firm's proprietary array using a machine-learning algorithm.

Earlier this month, GeneCapture scientists presented data collected from the functioning prototype system for its collaborators at the University of Alabama (Huntsville, AL, USA). They tested four antibiotics: ampicillin (AMP), amoxicillin/clavulanate (AMC), trimethoprim/sulfamethoxazole (SXT), and ciprofloxacin (CIP), against the nine pathogens responsible for most UTI cases. The group organisms include strains of species like Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, and Staphylococcus aureus.

The scientists initially evaluated 70 runs comparing 181 drug exposures to no-drug controls. They then evaluated 25 subsequent assays against culture results, focusing on AMP, AMC, SXT, and CIP, with most being tested in duplicate or triplicate. The group did not encounter false resistances or false sensitivities using the drugs. They also emphasized that the C-AST assay performed identically to culture results but in a much shorter period of time. The C-AST assay can test the effectiveness of various antibiotics against pathogens in between 5 and 75 minutes.

Peggy L. Sammon, co-founder and the CEO of GeneCapture, said, “We realized that for most infections, knowing the identity of the organism wasn't enough, so we developed the C-AST assay to give us information about the right drugs to use once CAPTURE has identified an organism. Knowing the type of organism and its concentration allows the C-AST assay to quickly analyze which antibiotics are sensitive or resistant."

Related Links:
University of Alabama


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Alzheimer's Disease Biomarker Assay
Elecsys Phospho-Tau (217P) Plasma
New
Drug Testing Assays
Atellica DT 250 Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: LVOne uses blood-based biomarkers to detect stroke and identify large vessel occlusion before hospital arrival, providing objective results earlier than traditional assessments. (Photo courtesy of UpFront Diagnostics)

First-of-Its-Kind Rapid Blood Test Gains CE Mark to Support Prehospital Stroke Triage

Rapid stroke identification before hospital arrival is critical because treatment efficacy declines with every minute of delay. However, definitive assessment typically requires hospital-based imaging,... Read more

Molecular Diagnostics

view channel
Image: MPNST is a cancer of the connective tissue surrounding peripheral nerves, with NF1 being a key risk factor (Image Credit: Nephron/Wikimedia Commons (CC BY-SA 3.0)

Liquid Biopsy Shows Promise for Detecting and Monitoring Malignant Nerve Sheath Tumors

Malignant peripheral nerve sheath tumor (MPNST) is one of the most serious cancers affecting people with neurofibromatosis type 1 (NF1), yet timely recognition remains difficult. Clinicians often struggle... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Central to the collaboration is the Enhanced Liver Fibrosis (ELF) test, a noninvasive blood test authorized in the U.S. to assess disease progression risk in patients with advanced fibrosis due to MASH and support patient management decisions. (Photo courtesy of Siemens Healthineers)

Siemens Healthineers and Novo Collaborate to Expand Access to Noninvasive Liver Testing

Metabolic dysfunction‑associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction‑associated steatohepatitis (MASH), affect millions and are linked to obesity, type 2 diabetes,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.